Takeda Accuses Watson Of Stepping On Gout Drug Patents

Law360, New York (February 28, 2014, 1:59 PM EST) -- Takeda Pharmaceuticals USA Inc. on Thursday launched a patent infringement suit against Watson Laboratories Inc. in Delaware federal court, seeking to prevent the generic-drug company from producing its own version of the gout treatment Colcrys.

Adding to its growing battle over Colcrys generics, Takeda accused Actavis Inc. subsidiary Watson Laboratories of planning to infringe on 14 patents related to the drug, which treats painful flares caused by severe arthritis, otherwise known as gout.

"Takeda will be irreparably harmed by Watson and Actavis' infringing activities unless those...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Takeda Pharmaceuticals USA Inc. v. Watson Laboratories Inc.


Case Number

1:14-cv-00268

Court

Delaware

Nature of Suit

Patent

Judge

Sue L. Robinson

Date Filed

February 27, 2014

Law Firms

Companies

Government Agencies

Patents